Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573143 | 1.00 | ACE (0.56) | ACEPPARAPPARGPTPN1PTPRA | |
| SCHEMBL29613833 | 1.00 | ACE (0.56) | ACEPPARAPPARGPTPN1PTPRA | |
| SCHEMBL215179 | 1.00 | ACE (0.56) | ACEPPARAPPARGPTPN1PTPRA | |
| SCHEMBL268002 | 1.00 | ACE (0.56) | ACEPPARAPPARGPTPN1PTPRA | |
| SCHEMBL8138118 | 0.91 | ACE (0.59) | ACEPTPN1ITGB3ITGA2BCTSS | |
| SCHEMBL5045604 | 0.91 | ACE (0.48) | ACEPPARAPPARGPTPN1PTPRA | |
| SCHEMBL5671145 | 0.91 | ACE (0.59) | ACEPTPN1ITGB3ITGA2BCTSS | |
| SCHEMBL16228483 | 0.91 | ATM (0.50) | ACEPPARAPPARGPTPN1PTPRA | |
| SCHEMBL16228480 | 0.91 | ATM (0.50) | ACEPPARAPPARGPTPN1PTPRA | |
| SCHEMBL16118683 | 0.91 | ATM (0.50) | ACEPPARAPPARGPTPN1PTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4516301-A2 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4166539-B1 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | PFIZER (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-114681443-B | Nitrile-containing antiviral compounds | 辉瑞大药厂 | 2024-05-10 | — | — | CN | disclosed |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-09 | — | — | US | disclosed |
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-1999051215-A2 | IMMUNOSUPPRESSIVE IMIDAZOLE DERIVATIVES AND THEIR COMBINATION PREPARATIONS WITH TACROLIMUS OR CYCLOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
| US-5932737-A | BENZOFURANYL- OR BENZOTHIENYL-TERMINATED | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| EP-0784629-B1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | DARWIN DISCOVERY LTD (GB) | 1999-04-28 | — | — | EP | disclosed |
| EP-0796270-A2 | PEPTIDE COMPOUNDS FOR PREVENTION AND/OR TREATMENT OF NO-MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-24 | — | — | EP | disclosed |
| WO-1996016981-A2 | PEPTIDE COMPOUNDS FOR PREVENTION AND/OR TREATMENT OF NO-MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-06 | — | — | WO | disclosed |
| US-5393875-A | Hypotensive, cardiotonic and antiischemic agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0509354-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-21 | — | — | EP | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
| US-4504414-A | Synthetic pyridyl-alanyl decapeptides having antiovulatory activity | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1985-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | ACE 71/4885PPARA 4811/4885PPARG 4815/4885 |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | ACE 5/4885PPARA 3763/4885PPARG 4400/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | ACE 77/4885PPARA 4208/4885PPARG 4358/4885 |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | ACE, ACE2, TMPRSS2 | ACE 1/4885PPARA 1772/4885PPARG 3183/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | ACE 77/4885PPARA 4208/4885PPARG 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.